JP2020527582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527582A5 JP2020527582A5 JP2020502586A JP2020502586A JP2020527582A5 JP 2020527582 A5 JP2020527582 A5 JP 2020527582A5 JP 2020502586 A JP2020502586 A JP 2020502586A JP 2020502586 A JP2020502586 A JP 2020502586A JP 2020527582 A5 JP2020527582 A5 JP 2020527582A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- phenylalanine
- ethoxycarbonylpiperazide
- triisopropylphenylsulfonyl
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 23
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- -1 2,4,6-triisopropylphenylsulfonyl Chemical group 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 11
- GKNUOVITASQZAQ-AWEZNQCLSA-N ethyl 4-[(2s)-2-amino-3-phenylpropanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](N)CC1=CC=CC=C1 GKNUOVITASQZAQ-AWEZNQCLSA-N 0.000 claims description 9
- 239000013078 crystal Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000002207 metabolite Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- FGYMBVGBIYRUHB-UQKRIMTDSA-N ethyl 4-[(2S)-2-amino-3-phenylpropanoyl]piperazine-1-carboxylate sulfuric acid Chemical compound S(=O)(=O)(O)O.C(C)OC(=O)N1CCN(CC1)C([C@@H](N)CC1=CC=CC=C1)=O FGYMBVGBIYRUHB-UQKRIMTDSA-N 0.000 claims description 4
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 3
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 238000000034 method Methods 0.000 description 20
- 239000012472 biological sample Substances 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 102100034396 Trypsin-3 Human genes 0.000 description 3
- 101710119642 Trypsin-3 Proteins 0.000 description 3
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 102100034392 Trypsin-2 Human genes 0.000 description 1
- 101710119666 Trypsin-2 Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762535376P | 2017-07-21 | 2017-07-21 | |
| US62/535,376 | 2017-07-21 | ||
| US201762574449P | 2017-10-19 | 2017-10-19 | |
| US62/574,449 | 2017-10-19 | ||
| US201762589734P | 2017-11-22 | 2017-11-22 | |
| US62/589,734 | 2017-11-22 | ||
| PCT/IB2018/000881 WO2019016595A1 (en) | 2017-07-21 | 2018-07-13 | USE OF WX-UK1 AND ITS PRODRANT WX-671 FOR THE TREATMENT OF NON-CANCER MEDICAL DISEASES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020527582A JP2020527582A (ja) | 2020-09-10 |
| JP2020527582A5 true JP2020527582A5 (https=) | 2021-08-12 |
Family
ID=65014605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502586A Pending JP2020527582A (ja) | 2017-07-21 | 2018-07-13 | 非癌性医学的状態の治療のためのｗｘ−ｕｋ１及びそのプロドラッグ、ｗｘ−６７１の使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190022088A1 (https=) |
| EP (1) | EP3654979A4 (https=) |
| JP (1) | JP2020527582A (https=) |
| KR (1) | KR20200031567A (https=) |
| CN (1) | CN110785172A (https=) |
| AU (1) | AU2018303799A1 (https=) |
| CA (1) | CA3070037A1 (https=) |
| CL (1) | CL2020000096A1 (https=) |
| IL (1) | IL271878A (https=) |
| PH (1) | PH12019502817A1 (https=) |
| RU (1) | RU2020107706A (https=) |
| SG (1) | SG11201912043QA (https=) |
| WO (1) | WO2019016595A1 (https=) |
| ZA (1) | ZA201908545B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111494602B (zh) * | 2020-04-14 | 2023-06-02 | 广州领晟医疗科技有限公司 | 一种治疗急性胰腺炎的组合物及其用途 |
| CN111494392A (zh) * | 2020-04-14 | 2020-08-07 | 广州领晟医疗科技有限公司 | 一种用于治疗急性肺损伤的组合物及其应用 |
| CN113559100B (zh) * | 2021-08-30 | 2023-01-17 | 广州领晟医疗科技有限公司 | 一种治疗肺损伤的组合物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5534498A (en) * | 1992-01-30 | 1996-07-09 | Corvas International, Inc. | Trypsin inhibitors |
| US7342018B2 (en) * | 1998-07-20 | 2008-03-11 | Wilex Ag | Urokinase inhibitors and uses thereof |
| AU2003206945A1 (en) * | 2002-02-22 | 2003-09-09 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of proteinase inhibitors in the treatment of autoimmune diseases |
| DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
| EP3309556B1 (en) * | 2009-06-25 | 2020-04-08 | Prometheus Biosciences, Inc. | Methods for diagnosing irritable bowel syndrome |
-
2018
- 2018-07-13 WO PCT/IB2018/000881 patent/WO2019016595A1/en not_active Ceased
- 2018-07-13 EP EP18835233.0A patent/EP3654979A4/en not_active Withdrawn
- 2018-07-13 SG SG11201912043QA patent/SG11201912043QA/en unknown
- 2018-07-13 KR KR1020197037453A patent/KR20200031567A/ko not_active Ceased
- 2018-07-13 CA CA3070037A patent/CA3070037A1/en not_active Abandoned
- 2018-07-13 US US16/034,815 patent/US20190022088A1/en not_active Abandoned
- 2018-07-13 RU RU2020107706A patent/RU2020107706A/ru not_active Application Discontinuation
- 2018-07-13 JP JP2020502586A patent/JP2020527582A/ja active Pending
- 2018-07-13 CN CN201880042082.2A patent/CN110785172A/zh active Pending
- 2018-07-13 AU AU2018303799A patent/AU2018303799A1/en not_active Abandoned
-
2019
- 2019-12-13 PH PH12019502817A patent/PH12019502817A1/en unknown
- 2019-12-20 ZA ZA2019/08545A patent/ZA201908545B/en unknown
-
2020
- 2020-01-07 IL IL271878A patent/IL271878A/en unknown
- 2020-01-13 CL CL2020000096A patent/CL2020000096A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5922515B2 (ja) | 線維筋痛症候群の長期治療のためのミルナシプラン | |
| JP7312116B2 (ja) | 外傷後ストレス障害の治療用の製剤 | |
| KR102615565B1 (ko) | 리실 옥시다제 유사 2 억제제의 용도 | |
| JP2016516074A5 (https=) | ||
| JP2017526713A (ja) | 線維症を処置するためのセニクリビロック併用療法 | |
| TWI428130B (zh) | 治療急性躁狂症之藥學組成物及方法 | |
| JP2020527582A5 (https=) | ||
| EP1988898A2 (en) | Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin | |
| RS63296B1 (sr) | Metode lečenja depresije korišćenjem antagonista receptora oreksin-2 | |
| JP2016164165A5 (https=) | ||
| JP2018503644A5 (https=) | ||
| JP2020075933A (ja) | ストレス性疾患の予防および／または治療用医薬 | |
| Bolin | Use of oral sodium cromoglycate in persistent diarrhoea. | |
| CN116075302A (zh) | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 | |
| JP2023502355A (ja) | Ｓ１ｐ１受容体に関連する状態を処置する方法 | |
| PH12019502817A1 (en) | Use of wx-uk1 and its prodrug, wx-671, for the treatment of non-cancerous medical conditions | |
| TW202341997A (zh) | 用於治療腸胃疾病或病狀之神經活性類固醇 | |
| Yolles et al. | Serum sickness induced by bupropion | |
| KR102169590B1 (ko) | 염증성 질환, 자가면역 질환, 또는 이들의 조합을 예방 또는 치료하기 위한 약학적 조성물 및 이를 이용한 방법 | |
| CN114901270A (zh) | 治疗自闭症谱系障碍的症状的方法 | |
| KR20250056265A (ko) | 주요 우울 장애를 치료하기 위한 1-(나프탈렌-2-일)-3-아자비시클로[3.1.0]헥산 | |
| KR102466251B1 (ko) | 뇌소혈관 질환 치료용 약물 제조에서의 화합물의 응용 | |
| KR20120030542A (ko) | 리팍시민에 대한 전신 노출의 조절 | |
| Chey et al. | Two Years on Linaclotide: tolerability and Treatment Satisfaction in IBS-C Patients With and Without Diarrhea: presidential Poster: 1791 | |
| Guner et al. | A case of Crimean Congo hemorrhagic fever complicated with acalculous cholecystitis and intraabdominal abscess |